V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10354491 | 10058173 | 0 | 56 | null | 2018-06-28 | 2018-07-19 | ATEZOLIZUMAB + BEVACIZUMAB | 02 | null | R-EPOCH | 101869239 |
| 10358134 | 10058175 | 1.77 | 82 | Palliative (P) | 2020-01-10 | 2020-01-14 | Cisplatin + Etoposide po&iv 3 day | 2 | N | CISPLATIN + PEMETREXED | 101767308 |
| 10360895 | 10058180 | 1.7 | 73.5 | null | 2018-06-01 | 2018-06-09 | LOMUSTINE + PROCARBAZINE | 02 | null | CISPLATIN + ETOPOSIDE | 101609114 |
| 10362620 | 10058183 | 1.63 | 52 | Curative (C) | 2019-07-25 | 2019-11-28 | PONATINIB | 02 | N | LIPOSOMAL DOXORUBICIN | 101770265 |
| 10364294 | 10058184 | null | 47 | null | null | 2017-10-25 | null | 99 | null | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 100596677 |
| 10364816 | 10058185 | 1.69 | 65.8 | null | 2016-03-17 | 2016-03-17 | Docetaxel + Trastuzumab (Maint) | 02 | null | GEMTUZUMAB OZOGAMICIN | 101317114 |
| 10366416 | 10058188 | 1.85 | 49.9 | Palliative (P) | 2019-04-22 | 2020-03-22 | ETOPOSIDE | 02 | null | ANAGRELIDE | 101417409 |
| 10375316 | 10058194 | 1.82 | 78 | null | 2019-12-28 | 2020-01-04 | Bortezomib + MELPHALAN | null | null | RUCAPARIB | 100612893 |
| 10381938 | 10058198 | 1.73 | 68.5 | Disease modification (D) | 2018-12-08 | 2019-01-19 | CYCLOPHOSPHAMIDE + IDARUBICIN | 02 | null | CYCLOPHOSPHAMIDE + IDARUBICIN | 101748891 |
| 10384782 | 10058199 | 1.78 | 65 | null | 2019-02-05 | 2019-02-12 | Fulvestrant + Palbociclib | 02 | null | IRINOTECAN | 100920432 |
| 10389528 | 10058204 | 1.87 | 95 | null | null | 2017-09-26 | GEFITINIB | 02 | N | IRINOTECAN + MDG | 101248608 |
| 10391097 | 10058208 | 1.84 | 51.4 | 03 | 2019-11-23 | 2019-12-06 | Dasatinib | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101266589 |
| 10393976 | 10058211 | 1.78 | 87.6 | Neo-adjuvant (N) | 2020-11-21 | 2020-11-21 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | N | DOCETAXEL + TRASTUZUMAB | 101836180 |
| 10395753 | 10058214 | 1.67 | 83 | 03 | 2020-01-19 | 2020-01-23 | ABEMACICLIB + FULVESTRANT | 02 | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + METHOTREXATE + RITUXIMAB + VINCRISTINE | 101611413 |
| 10406530 | 10058226 | 1.63 | 90.1 | Palliative (P) | 2017-09-07 | 2017-10-01 | Pemetrexed | 02 | N | FLUOROURACIL + MITOMYCIN | 100252882 |
| 10407616 | 10058228 | 0 | 107.4 | null | 2019-11-14 | 2019-11-27 | EVEROLIMUS + EXEMESTANE | 02 | null | ELOQUENT2 TRIAL | 100748066 |
| 10407907 | 10058229 | 1.72 | 75 | Palliative (P) | 2016-12-04 | 2018-02-12 | Bexarotene | 02 | N | DOXORUBICIN EMBOLISATION | 100734335 |
| 10410017 | 10058230 | 1.63 | 84.2 | null | 2019-05-09 | 2020-07-31 | Obinutuzumab | 02 | null | DURVALUMAB | 100826149 |
| 10410721 | 10058233 | 1.61 | 81 | null | 2014-06-07 | 2020-03-09 | Carboplatin + Docetaxel | N | null | CAPECITABINE + CISPLATIN | 101109753 |
| 10413699 | 10058235 | 1.62 | 116 | Palliative (P) | 2019-08-10 | 2019-08-26 | Bevacizumab + Olaparib | null | N | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 100958792 |
| 10417622 | 10058238 | 1.72 | 74.3 | null | 2021-02-01 | 2021-02-25 | Irinotecan + Modified De Gramont | 02 | null | IRINOTECAN | 101605680 |
| 10418705 | 10058239 | 1.6 | 62.2 | Palliative (P) | 2019-07-16 | 2019-11-16 | Gemcitabine + Oxaliplatin | 02 | N | EVEROLIMUS + EXEMESTANE | 101159646 |
| 10421790 | 10058242 | 1.82 | 61.1 | Adjuvant (A) | null | 2019-08-04 | BEP 3 day | 02 | N | CAR-T AXICABTAGENE CILOLEUCEL + CYCLOPHOSPHAMIDE + FLUDARABINE | 100885565 |
| 10428682 | 10058246 | 1.73 | 93.4 | null | 2022-05-12 | 2022-05-30 | Sunitinib | 02 | null | THALIDOMIDE | 101230157 |
| 10429245 | 10058247 | null | null | Palliative (P) | 2022-04-19 | 2022-04-19 | Erlotinib | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101686829 |
| 10431345 | 10058249 | 1.86 | 63.9 | null | 2017-11-21 | 2017-11-22 | Cyclophosphamide + Docetaxel + Trastuzumab | 02 | null | ALECTINIB | 101540212 |
| 10433066 | 10058251 | 0 | 84.5 | null | 2018-04-16 | 2018-04-25 | IDELALISIB + RITUXIMAB | 02 | null | NILOTINIB | 100883142 |
| 10440335 | 10058257 | 1.6 | 79.15 | null | 2019-10-15 | 2019-12-31 | Irinotecan 14day | 02 | null | OLAPARIB | 101048389 |
| 10443120 | 10058259 | 1.82 | 53.5 | null | 2021-06-28 | 2021-06-29 | VISMODEGIB | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100256812 |
| 10444398 | 10058260 | 1.55 | 62.6 | 03 | 2018-06-27 | 2018-08-15 | CRIZOTINIB | 02 | N | BEVACIZUMAB | 100255588 |
| 10451760 | 10058264 | null | null | null | 2022-03-16 | 2022-03-21 | null | 02 | null | DOXORUBICIN + OLARATUMAB | 100654333 |
| 10453120 | 10058266 | 1.88 | 69.5 | Palliative (P) | 2017-01-18 | 2017-05-25 | Capecitabine + Mitomycin | 02 | N | ETOPOSIDE | 101099372 |
| 10453660 | 10058267 | 1.69 | 91 | Palliative (P) | 2016-07-10 | 2016-07-24 | null | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101746091 |
| 10458735 | 10058269 | 1.67 | 56.05 | Palliative (P) | 2021-09-09 | 2021-09-23 | AZACITIDINE + VENETOCLAX | null | null | CISPLATIN + FLUOROURACIL + RT | 101831925 |
| 10464834 | 10058278 | 1.66 | 50.8 | null | 2021-01-19 | 2022-02-11 | Sunitinib | 02 | null | ETOPOSIDE | 100372596 |
| 10465770 | 10058280 | 1.61 | 96.9 | null | 2019-05-10 | 2019-05-18 | Cape+Cisplatin+Trastuzumab Main | 02 | null | CAPECITABINE + CARBOPLATIN | 100092830 |
| 10467063 | 10058284 | 0 | 77 | 03 | 2019-06-22 | 2020-02-04 | Cape+Cetuximab+Oxalip (2 wk) Maint | 01 | N | CARBOPLATIN + FLUOROURACIL | 101032305 |
| 10467459 | 10058285 | 1.73 | 50.85 | null | 2020-09-20 | 2020-10-18 | DA-EPOCH-R | 02 | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 100466048 |
| 10477519 | 10058292 | null | null | Palliative (P) | 2019-07-17 | 2019-07-20 | CHOP - 21 days | 02 | N | MERCAPTOPURINE | 100200915 |
| 10479899 | 10058294 | 1.76 | 83.7 | null | 2018-11-09 | 2018-11-23 | CISPLATIN + RT | 02 | N | SUNITINIB | 101715823 |
| 10480742 | 10058296 | 1.65 | 80 | Palliative (P) | 2019-12-05 | 2019-12-24 | EVEROLIMUS | N | N | IPILIMUMAB | 101861899 |
| 10136138 | 10058298 | 1.68 | 89 | 03 | 2021-10-24 | 2021-10-29 | null | 02 | N | FULVESTRANT + PALBOCICLIB | 101813023 |
| 10140286 | 10058299 | 1.75 | 80.6 | Palliative (P) | 2022-04-30 | 2022-05-06 | VISMODEGIB | 02 | N | GEFITINIB | 101061635 |
| 10161782 | 10058300 | 1.72 | 81.9 | 03 | 2019-08-08 | 2019-08-09 | Trial Unspecified | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101686103 |
| 10219469 | 10058301 | 1.68 | 65.8 | Palliative (P) | 2018-03-18 | 2018-06-02 | Trial Unspecified | 01 | N | CYCLOPHOSPHAMIDE + VINCRISTINE | 101437340 |
| 10235674 | 10058303 | 1.83 | null | Neo-adjuvant (N) | 2020-03-02 | 2020-03-09 | Folfirinox | 02 | N | TRIAL | 101861152 |
| 10304540 | 10058312 | 1.67 | 76.05 | Neo-adjuvant (N) | 2020-12-26 | 2020-12-26 | CAPECITABINE + CARBOPLATIN | 2 | N | ANTI-THYMOCYTE GLOBULIN + BUSULFAN + FLUDARABINE | 101609384 |
| 10330421 | 10058315 | 1.57 | 59.8 | Palliative (P) | 2021-09-10 | 2021-09-12 | Fulvestrant + Ribociclib | N | N | AML18 TRIAL | 100171223 |
| 10331943 | 10058317 | null | null | null | 2020-02-18 | 2020-04-22 | Mitomycin Intravesical | 02 | null | IRINOTECAN | 100062157 |
| 10457743 | 10058330 | 1.68 | 0 | Palliative (P) | null | 2021-11-19 | Cisplatin + Pemetrexed | 02 | N | IRINOTECAN | 100085056 |